| Old Articles: <Older 8571-8580 Newer> |
|---|
 |
Pharmaceutical Executive
February 1, 2013
Julin et al. |
Fortuity and the First Amendment Caronia decision shows the staying power of Sorrell v. IMS Health. Don't bank just yet on putting your marketing muscle behind the safe and effective off-label uses of your FDA-approved drugs.   |
Pharmaceutical Executive
February 1, 2013
Jill Wechsler |
Breakthrough Year for New Drugs More new medicines gained market approval, but marketers face resistance from payers looking to cut healthcare spending. |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
Chemistry World
February 8, 2013
Rachel Cooper |
Printing crystalline drugs A group of UK chemists has used a desktop inkjet printer to prepare a metastable form of the anti-epileptic drug carbamazepine. |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
Chemistry World
February 7, 2013
Maria Burke |
GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public. |
Chemistry World
February 1, 2013
Andrew Turley |
Zoetis IPO launches at $2.2bn The separation of Pfizer from its animal health business, Zoetis, has begun. Pfizer has priced its initial public offering of 86 million shares at $26 per share, for a total of $2.2 billion |
Pharmaceutical Executive
January 1, 2013
Ben Comer |
Compliance in the C-Suite Compliance officers have risen into pharmaceutical management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated. |
Pharmaceutical Executive
January 1, 2013 |
Product Liability Claims and Comment K Courts across the country are making it easier to prove that a drug is unsafe, warning label notwithstanding. |
Chemistry World
January 25, 2013
Andrew Turley |
Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million |
| <Older 8571-8580 Newer> Return to current articles. |
